On Friday, Shares of Calithera Biosciences Inc (NASDAQ:CALA), lost -5.28% to $7.18.
Calithera Biosciences Inc, declared at the JMP Securities Life Sciences Conference in New York City, the selection of CB-1158 as the clinical candidate for their immuno-oncology program targeting inhibition of arginase, a critical immunosuppressive enzyme secreted by myeloid-derived suppressor cells (MDSCs) in tumors. Calithera anticipates submitting an Investigational New Drug (IND) application to the FDA for its first in class oral arginase inhibitor for the treatment of cancer near the end of the first quarter of 2016. Arginase exerts its immunosuppressive effect by depleting the amino acid arginine in the tumor microenvironment and preventing the immune system’s cytotoxic T-cells and natural killer (NK) cells from proliferating and killing the tumor. Inhibition of arginase activity reverses this immunosuppressive block and restores T-cell function.
“We believe that drugs targeting metabolism pathways have the potential to be transformational in the treatment of cancer. At Calithera, we are dedicated to researching and developing first-in-class metabolism- targeted therapies that could significantly advance the field of immuno-oncology,” said Susan M. Molineaux, PhD, President and CEO, Calithera Biosciences. “We are particularly excited about the potential of our small molecule arginase inhibitors to treat cancer by blocking the immune-suppression of MDSCs and activating the immune system to kill tumors.”
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States.
Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), inclined 2.74% to $23.61, during its last trading session.
Momenta Pharmaceuticals, declared that Rick Shea has advised the Company of his intention to step down as Chief Financial Officer (CFO) once a successor is identified and designated. Mr. Shea will remain with the Company to assist with the CFO succession and serve in a newly created role of Senior Vice President, Corporate Communications and Operations for a transition period preceding to his planned retirement in 2016. Momenta has initiated a CFO search.
“For the past 12 years Rick has played a central role in Momenta’s transition from a start-up R&D company into the growing product development company we are recently,” said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. “Rick’s leadership, guidance and unwavering commitment to Momenta has been a vital part of our growth as a business — and for that we thank him. I am also grateful that Rick has agreed to stay on through this transition period and thank him for his many contributions that have better positioned the Company for sustainable growth and success.”
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases.
At the end of Friday’s trade, Shares of Radius Health Inc (NASDAQ:RDUS), gained 0.79% to $63.93.
Radius Health, reported top line data from the first six months of ACTIVExtend and the 25 month combined data from ACTIVE and ACTIVExtend. Additionally, Radius is reporting new data from an exploratory analysis of major osteoporotic fractures in the ACTIVE trial.
Radius formerly stated positive results in December 2014 for the Phase 3 ACTIVE Trial — meeting the primary endpoint of new vertebral fracture reduction (-86%, p < 0.0001) and secondary endpoints of non-vertebral fracture reduction (-43%, p = 0.0489) and BMD enhances at Spine (18M, 9.20% p < 0.0001), Femoral Neck (18M 2.90% p < 0.0001) and Total Hip (18M 3.44% p < 0.0001).
Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States.
Finally, Valeant Pharmaceuticals Intl Inc (NYSE:VRX), ended its last trade with -2.10% loss, and close at $228.83.
Valeant Pharmaceuticals International, declared that it will host a conference call and a live Internet webcast together with a slide presentation on Thursday, July 23, 2015 at 8:00 a.m. ET (5:00 a.m. PT) to talk about results for the 2015 second quarter.
The dial-in number to take part on this call is (877) 876-8393, confirmation code 73333543. International callers should dial (973) 200-3961, confirmation code 73333543. A replay will be accessible about two hours following the conclusion of the conference call to Wednesday, September 23, 2015 , and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 73333543.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
